Lijun Pharmaceutical (Guangzhou) Co., Ltd., rooted in the strategic position of the Guangdong-Hong Kong-Macao Greater Bay Area, deeply cultivates the pharmaceutical field with a cutting-edge attitude. With R&D as the core and products as the foundation, it builds strong market competitiveness, demonstrating the core strength of a new-generation pharmaceutical enterprise.

Relying on the group’s national-level technology center and postdoctoral research station, the company has a high-quality R&D team, focusing on core areas such as anti-infection and cardio-cerebrovascular diseases, and devoting to process optimization and characteristic preparation R&D. It has obtained multiple intellectual property rights with leading technology in macrolide antibiotics, forming an R&D pattern of "classic iteration + innovative reserve". Its products adhere to the concept of "excellent quality", with a strict full-chain quality control system. Core products have passed FDA and COS international certifications, sold overseas. With advantages in technical barriers, quality and regional channels, it firmly occupies the South China market, leading the industry steadily.